David L. Blumberg has more than 20 years of business and consulting experience across the life sciences continuum, including global, specialty, and generic pharmaceuticals, biotech, and medical devices and products. Mr. Blumberg recently retired from KPMG where he led their U.S. Pharmaceuticals and Life Sciences Advisory practice. Previously, he was the Executive Vice President of Professional Services and Customer Support of a public software company that specializes in contract and demand management for life sciences corporations. He spent several years at Accenture, where he served as lead partner for the Pharmaceutical and Medical Products Industries and led one of the corporation’s largest account relationships. Mr. Blumberg has an M.B.A. from The Wharton School and a B.S. degree in mechanical engineering from Ohio State University. He is a guest lecturer at The Wharton School, the Harvard Business School and at the New York Institute of Technology. Mr. Blumberg also serves on the Board of Advisors for the Vagelos Life Sciences and Management Program at The Wharton School and the University of Pennsylvania.
Aeras is a nonprofit biotechnology organization developing new, effective tuberculosis (TB) vaccines that are affordable and accessible to all who need them. We work through partnerships in both the public and private sectors, with individuals, research organizations, academic institutions, funders, policymakers and others around the world to advance TB vaccine science and development.
Over the past decade, Aeras has made significant contributions to the marked progress of the TB vaccine field. Together with our partners and collaborators, we are advancing the best TB vaccine science and working toward a common goal of ending the threat of TB. Aeras’s headquarters are located in Rockville, Maryland, with offices in Cape Town, South Africa and Beijing, China.